Back

Cardiotoxicity following BRAF and MEK inhibitor therapy: a meta-analysis of prevalence

19 June 2026 (10:54 - 11:03)
Organised by: Logo
Congress Presentation Part of: Stratifying the risk of cardiotoxicity Stratification, Prevention and Monitoring Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor David Koeckerling

University Hospital Heidelberg, Heidelberg (Germany)

4 More presentations in this session

Presentation thumbnail
Coronary artery calcium quantification on routine contrast-enhanced CT-scans in patients with cancer receiving immune checkpoint inhibitors: a prospective cohort study
Miss A. Strijdhorst (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Baseline and early changes in cardiac biomarkers as predictors of global longitudinal strain deterioration during breast cancer therapy: a PRADAII substudy
Doctor V. Vinje (Nordbyhagen, NO)
Abstract Slides
Presentation thumbnail
Evaluating standard risk prediction tools for predicting cardiotoxicity in patients receiving fluoropyrimidine chemotherapy
Doctor A. Abiodun (London, GB)
Abstract Slides
Presentation thumbnail
Sex influence on cancer incidence after a cardiovascular event: a population study
Doctor H. Morillas Climent (Barcelona, ES)
Abstract Slides

Access the full session

Session thumbnail
Stratifying the risk of cardiotoxicity
Video

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 10:54 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources